Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 744 participants.
Also called NCT01076088
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 744 participants
- Sponsor
- Registry
-
NCT01076088
-
- Other papers using this trial's data
- Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01076088. Randomized; double masking; primary purpose treatment. Start 2010-11-15 (actual); primary completion 2012-12-24 (actual). Results posted on 2014-02-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sitagliptin 50 mg
- Intervention (Drug)
- Metformin 500 mg
- Intervention (Drug)
- Sitagliptin 100 mg
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Metformin 850 mg
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01076088- Content hash
f4fc9e45656b1899b2be930764263717def57f7e57f80a6bfdc2b97524a2a3cf